Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Assets Average: 2016-2025

Historic Assets Average for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $394.5 million.

  • Rocket Pharmaceuticals' Assets Average fell 6.08% to $394.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year decrease of 6.08%. This contributed to the annual value of $547.0 million for FY2024, which is 2.16% down from last year.
  • Rocket Pharmaceuticals' Assets Average amounted to $394.5 million in Q3 2025, which was down 11.55% from $446.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Assets Average registered a high of $583.7 million during Q1 2021, and its lowest value of $394.5 million during Q3 2025.
  • For the 3-year period, Rocket Pharmaceuticals' Assets Average averaged around $487.3 million, with its median value being $488.3 million (2023).
  • Its Assets Average has fluctuated over the past 5 years, first spiked by 56.71% in 2021, then declined by 20.92% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Assets Average (Quarterly) stood at $513.6 million in 2021, then decreased by 5.66% to $484.5 million in 2022, then rose by 20.23% to $582.6 million in 2023, then dropped by 20.92% to $460.7 million in 2024, then dropped by 6.08% to $394.5 million in 2025.
  • Its Assets Average stands at $394.5 million for Q3 2025, versus $446.0 million for Q2 2025 and $499.4 million for Q1 2025.